以肠道菌群为辅助的结直肠癌免疫治疗进展及未来展望

Progress and future prospects of immunotherapy for colorectal cancer assisted by gut flora

结直肠癌(colorectal cancer,CRC)是世界范围内的高发病、高死亡疾病,其病因多且交错。多研究证实,结直肠肿瘤免疫疗法的效果和并发症与特定肠道微生物群的组成有关,调节这部分菌群的辅助治疗有望促进CRC免疫治疗效果最大化。本文就总结肠道菌群作用在CRC免疫治疗中的科学证据,重点是特定菌群及菌群调节相关治疗方案在CRC免疫治疗中的现状作一概述。

Colorectal cancer(CRC)is a disease with high morbidity and high mortality worldwide,and its etiology is multiple and intertwined.Multiple studies have confirmed that the effects and complications of colorectal tumor immunotherapy are related to the composition of specific gut microbiota,and adjuvant therapy that modulates this part of the microbiota is expected to maximize the effect of CRC immunotherapy.We summarized the scientific evidence for the role of gut microbiota in CRC immunotherapy,focusing on the current status of specific microbiota and microbiota modulation-related treatment regimens in CRC immunotherapy.